Sihe Zhang

11PUBLICATIONS
8CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisInstrumental methods (excl. immunological and bioassay methods)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 15, 2026
CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.

|Mar 30, 2026
HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering.

Jiliang Zhao, Dongping Zhang, Yun-Yueh Lu

|May 22, 2025
27-Hydroxycholesterol in cancer development and drug resistance.

Yaxin Hou, Zhiguang Fu, Chenhui Wang

|May 10, 2025
Gelatin Zymography: Principle, Method and Application in Cancer Research.

Luomeng Qian, Sihe Zhang

|Mar 12, 2024
Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity.

Fang-Zheng Qi, Hui-Shan Su, Bo Wang

|Jul 29, 2023
Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress.

Zhe Sun, Jinhai Huang, Zvi Fishelson

Pageof 2

Frequent Collaborators

2 joint publications

Jinhai Huang

1 joint publications

Zongjin Li

1 joint publications

Yazhuo Du

1 joint publications

Kunkun Ge